Arbutus Biopharma

Arbutus Biopharma Corp. is a biopharmaceutical company. It engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Arbutus Biopharma advances promising drug candidates and secures financial stability

Arbutus Biopharma showcased progress in its drug development pipeline, particularly with positive Phase IIa trial results for AB-729 and the introduction of AB-343 as a promising oral coronavirus drug candidate. The company's financial stability and strategic focus on upcoming milestones position it well for future growth.

Arbutus Biopharma advances HBV and COVID-19 treatments with strong finances

Arbutus Biopharma is making significant progress in developing treatments for HBV and COVID-19, supported by a strong financial position.
While facing challenges such as FDA clinical holds and trial planning, the company is well-positioned to capitalize on upcoming opportunities.
Strategic focus on clinical advancements, financial stability, and future growth opportunities defines Arbutus Biopharma's outlook for 2023.

Arbutus Biopharma advances Hepatitis B cure development amid financial strength

Arbutus Biopharma is progressing well in its quest for a functional cure for chronic Hepatitis B, supported by a strong pipeline and financial stability.
The company faces challenges in navigating development hurdles and competition but has opportunities to lead in innovative therapies for HBV and COVID-19.
By focusing on key milestones, strategic trial designs, and effective resource management, Arbutus aims to drive growth and success in the biopharmaceutical sector.

Arbutus Biopharma focuses on HBV cure amid leadership transition

Arbutus Biopharma's strategic focus on developing a functional cure for chronic HBV and maintaining financial stability through 2026 positions the company for future growth.
While workforce reduction and legal challenges present hurdles, the company's pipeline progress and leadership transition signal resilience and adaptability.
Opportunities in pipeline expansion, partnerships, and clinical trial advancements underscore Arbutus Biopharma's potential for long-term success in the biopharmaceutical industry.

Arbutus Biopharma focuses on HBV cure, extends cash runway

Arbutus Biopharma's Q4 2023 earnings call highlighted a strategic focus on HBV and extending cash runway. Progress in clinical trials and ongoing litigation efforts against key players. Anticipating reduced cash burn in 2024 for financial sustainability.

Arbutus Biopharma reports strong financials and progresses HBV treatment pipeline

Arbutus Biopharma showcased a strong financial position and positive results in Phase 1a study of AB-836.
The company's focus on developing a functional cure for chronic HBV and advancing pipeline assets demonstrates commitment to innovation.
While facing questions on dosing strategies and trial designs, Arbutus sees opportunities in upcoming data releases and advancing clinical studies.

Arbutus Biopharma reports promising HBV trial results and financial strength

Arbutus Biopharma demonstrates positive trial results and financial stability, positioning the company well for future growth and innovation in HBV treatment
Challenges in trial design, data interpretation, and legal proceedings require careful navigation to capitalize on opportunities for advancement
Opportunities lie in further data reporting, biomarker exploration, and potential partnerships to drive progress towards a functional cure for chronic hepatitis B

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

WARMINSTER, Penn., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that the Company will participate in the following October investor conferences:

Arbutus to Participate in October Investor Conferences

Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.

Do Options Traders Know Something About Arbutus Biopharma (ABUS) Stock We Don't?

WARMINSTER, Pa., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced the Company has appointed Lisa M. Caperelli to the newly created position of Vice President of Investor Relations, leading investor relations strategy and communications activities, reporting to David Hastings, Arbutus' Chief Financial Officer.

Arbutus Appoints Lisa M. Caperelli as Vice President, Investor Relations

The stock price of Arbutus Biopharma Corp (NASDAQ: ABUS) increased more than 12.5% over the past few trading days. This is why it happened.

ABUS Stock: Why It Increased This Week

Is the Options Market Predicting a Spike in Arbutus Biopharma (ABUS) Stock?

Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q2 2021 Results - Earnings Call Transcript

New data on AB-729, Arbutus' proprietary subcutaneously delivered RNAi agent, highlighted in four abstracts at the EASL International Liver Congress™ ; all AB-729 abstracts selected for best of ILC™

Arbutus Reports Second Quarter 2021 Financial Results and Provides Corporate Update

WARMINSTER, Pa., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that the Company will participate in a fireside chat at the Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 10, 2021 at 4:05 PM ET.

Arbutus to Present at Wedbush PacGrow Healthcare Virtual Conference

WARMINSTER, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that it has scheduled its second quarter 2021 financial results and corporate update for Thursday, August 5, 2021. The schedule for the press release and conference call/webcast are as follows:

Arbutus to Report Second Quarter 2021 Financial Results and Provide Corporate Update

Aerpio Pharmaceuticals Inc

Corbus Pharmaceuticals Holdings

Digital Brands Group Inc

9F Inc - ADR

NovaBay Pharmaceuticals

NexGen Energy

Why investors are watching these 7 penny stocks right now The post Which Penny Stocks Are Investors Buying Right Now? 7 For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Which Penny Stocks Are Investors Buying Right Now? 7 For Your Watchlist

Phase 2a trial to investigate the safety and anti-viral activity of AB-729 in combination with ongoing nucleos(t)ide analog (NA) therapy and short courses of Peg-IFNα-2a in subjects with chronic hepatitis B virus infection (CHB)

Arbutus Receives Authorization to Proceed with an Investigational New Drug Application (IND) for AB-729, its Proprietary Subcutaneously-Delivered RNAi Agent

The expected start of combination clinical trials has H.C. Wainwright bullish on shares of Arbutus Biopharma Corp. (NASDAQ:ABUS).

Bullish Arbutus Biopharma Analyst Breaks Down Pipeline Opportunity

Vaccitech

Arbutus Biopharma Corporation (NASDAQ: ABUS) and Vaccitech plc (NASDAQ: VACC) have collaborated to evaluate combination treatment for chronic hepatitis B virus who are already receiving standard-of-care nucleos(t)ide reverse transcriptase inhibitor (NrtI) therapy. The Phase 2a trial will evaluate the safety, pharmacokinetics, immunogenicity, and antiviral activity of Arbutus's AB-729, followed by Vaccitech's VTP-300, in NrtI-suppressed subjects.

Arbutus Biopharma, Vaccitech Team Up To Develop Combo Treatment For Hepatitis B

WARMINSTER, Pa. and OXFORD, United Kingdom, July 06, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) and Vaccitech plc (Nasdaq: VACC) today announced that the companies have entered into a clinical trial collaboration agreement to evaluate an innovative therapeutic combination for the treatment of subjects with chronic hepatitis B virus (HBV) infection (CHB) who are already receiving standard-of-care nucleos(t)ide reverse transcriptase inhibitor (NrtI) therapy.

Arbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement to Evaluate RNAi Therapeutic, AB-729, in Combination with Immunotherapeutic, VTP-300, in Subjects with Chronic Hepatitis B Virus Infection

Arbutus presented five abstracts at EASL International Liver Congress 2021, one presentation dealing with long-term dosing of AB-729 for Hepatitis B patients was given as a late-breaker oral presentation.

Arbutus' Recent Hepatitis B Data At EASL 2021 Makes The Case For A Great Long-Term Investment

MENDHAM, N.J. and WARMINSTER, Pa., June 29, 2021 (GLOBE NEWSWIRE) -- Antios Therapeutics, Inc. and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the companies have entered into a clinical collaboration agreement to evaluate a triple combination of Arbutus' proprietary GalNAc delivered RNAi therapeutic, AB-729, Antios' proprietary active site polymerase inhibitor nucleotide (ASPIN), ATI-2173, and Viread (tenofovir disoproxil fumarate), for the treatment of subjects with chronic hepatitis B virus (HBV) infection.

Arbutus Biopharma and Antios Therapeutics Announce Clinical Collaboration Agreement to Evaluate AB-729 in Combination with ATI-2173 in Subjects with Chronic Hepatitis B Virus Infection

Marin Software

Safe Bulkers

United States Antimony

Ashford Hospitality Trust

Senseonics Holdings

Tonix Pharmaceuticals Hld

Are these hot penny stocks on your morning watchlist? The post Best Penny Stocks to Buy Right Now?

Best Penny Stocks to Buy Right Now? 7 Small-Caps For Your Morning List

Arbutus Biopharma Corporation (NASDAQ: ABUS) announced the presentation of five abstracts at the European Association for the Study of the Liver International Liver Congress for AB-729 in chronic hepatitis B and AB-836 programs. AB-729 demonstrated robust mean HBsAg reduction across all doses and dosing intervals with a favorable safety and tolerability profile, followed by a sustained plateau phase.

Arbutus Biopharma Stock Jumps On Encouraging Data From Hepatitis B Candidate

The stock price of Arbutus Biopharma Corp (NASDAQ: ABUS) increased by over 15% pre-market. This is why it happened.

ABUS Stock Price Increased Over 15% Pre-Market: Why It Happened

AB-729, dosed at 60 mg every 8 weeks, achieved a mean HBsAg decline of -1.87 log10 IU/mL at week 44, comparable to 60 mg dosed every 4 weeks

Arbutus Announces New Data on AB-729 and AB-836 Programs with Presentation of Five Abstracts at the EASL International Liver Congress™ 2021 - All Selected for Best of ILC™

Conference Call and Webcast to discuss the new data being presented at EASL  scheduled for 8:00 AM ET, Monday, June 28, 2021

Arbutus Announces Multiple Abstracts Accepted for Oral and Poster Presentations at the EASL 2021 International Liver Congress in June

Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q1 2021 Results - Earnings Call Transcript

AB-729, Arbutus' proprietary subcutaneously delivered RNAi agent, continues to demonstrate robust and continuous declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B (HBV) with favorable safety and tolerability data

Arbutus Reports First Quarter 2021 Financial Results and Provides Corporate Update

WARMINSTER, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that it has scheduled its first quarter 2021 financial results and corporate update for Wednesday, May 5, 2021. The schedule for the press release and conference call/webcast are as follows:

Arbutus to Report First Quarter 2021 Financial Results and Provide Corporate Update

Arbutus Biopharma Corp (NASDAQ: ABUS), X-Chem Inc, and Proteros biostructures GmbH have entered into discovery, research, and license agreement focused on discovering novel inhibitors targeting the SARS-CoV-2 nsp5 main protease (Mpro). The collaboration's goal is to identify safe and effective therapies against coronaviruses, including SARS-CoV-2.

News for Arbutus Biopharma Stock (ABUS)